New study updates evidence on rare blood-clotting condition after covid-19 vaccination
Based on health data from five European countries and the US, it shows a small increased risk of TTS after a first dose of the Oxford-AstraZeneca vaccine, and a trend towards an increased risk after the Janssen/Johnson & Johnson vaccine, compared with the Pfizer-BioNTech vaccine.
Findings show small increased risk after adenovirus vaccines Should be considered when planning further immunisation campaigns and future vaccine development A study published by The BMJ today sheds further light on the risk of developing a very rare blood-clotting condition known as thrombosis...
www.bmj.com